Plasma Dabigatran Activity One Week After Discontinuation Despite Normal Renal Function - 23/07/13
Doi : 10.1016/j.amjmed.2013.02.023
Jecko Thachil, MD ⁎ 
, Gill Pike, MD, Lynne Keighley-Jones, FIBMS, Michael J. Nash, MD
, Gill Pike, MD, Lynne Keighley-Jones, FIBMS, Michael J. Nash, MD Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom
∗Requests for reprints should be addressed to Jecko Thachil, MD, Department of Haematology, Manchester Royal Infirmary, Oxford Road, Manchester, UK M13 9WL.
Le texte complet de cet article est disponible en PDF.
| Funding: None. |
|
| Conflict of Interest: MJN has received speaker fees from Bayer. JT has received speaker fees from Bayer and Boehringer Ingelheim. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
© 2013
Elsevier Inc. Tous droits réservés.
Vol 126 - N° 8
P. e5-e6 - août 2013 Retour au numéro
Article précédent
- Eagle's Syndrome
- Christoph Becker, Jens Pfeiffer
- Thyrotoxicosis and Neck Pain: Getting the Right Test at the Right Time
- Shahid Aziz, Ali Rizvi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?